# Effects of Evolocumab Versus Placebo Added to Standard Lipid-lowering Therapy on Fasting and Post Fat Load Lipids in Patients With Familial Dysbetalipoproteinemia

> **NCT03811223** · PHASE4 · UNKNOWN · sponsor: **UMC Utrecht** · enrollment: 30 (estimated)

## Conditions studied

- Familial Dysbetalipoproteinemia
- Hyperlipoproteinemia Type III

## Interventions

- **DRUG:** Evolocumab Auto-Injector [Repatha]
- **DRUG:** Placebos

## Key facts

- **NCT ID:** NCT03811223
- **Lead sponsor:** UMC Utrecht
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-08
- **Primary completion:** 2021-01
- **Final completion:** 2021-03
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2019-01-22

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03811223

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03811223, "Effects of Evolocumab Versus Placebo Added to Standard Lipid-lowering Therapy on Fasting and Post Fat Load Lipids in Patients With Familial Dysbetalipoproteinemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03811223. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*